세계의 세포 및 유전자 치료 시장 : 질환 유형별 시장 동향, 개발, 동향과 예측(제4판, 2024-2030년)

Cell and Gene Therapy Market Dynamics by Disease Type: Development, Trends, and Forecasts, 4th Edition (2024-2030)

US $ 5,600 ￦ 7,887,000

Online only (3 Users, No Downloads)

US $ 8,000 ￦ 11,268,000

Online + Download (Unlimited users)

한글목차

본 보고서는 현대 의료에서 세포 치료 및 유전자 치료의 변화 가능성에 대해 전해드립니다. 이 치료법은 질병의 유전적 원인에 대처하고 면역계를 조절함으로써 획기적인 치료를 제공합니다.

또한 시장을 치료분야별로 분류하여 상세한 시장 추계 및 예측, 경쟁 구도에 관한 고찰을 제공하는 종합적인 보고서입니다.

주요 치료 분야는 다음과 같습니다.

본 보고서에서는 COVID-19의 RNA 요법과 감염증용 mRNA 백신은 제외하고 대신 광범위한 유전자 치료의 적용에 초점을 맞추었습니다.

조사 방법으로는 업계 관계자와의 인터뷰와 종합적인 문헌 조사 등 1차 조사와 2차 조사를 조합하고 있습니다. 시장의 하이라이트, 예측, 경쟁 분석을 제공하며 시장 지표, 동향, 장벽에 대해 논의합니다. 유전자 치료의 여명기이기 때문에 예측은 한정된 선행 사례에 근거하고 있어, 2024년 시장 규모 추계 및 예측과 2030년까지의 예측을 제공합니다.

본 보고서는 세포 치료와 유전자 치료의 진화 상황을 이해하기 위한 중요한 자료로서 도움이 되어 헬스케어와 생명공학 분야의 이해관계자에게 귀중한 인사이트를 제공합니다.

목차

제1장 주요 요약

제2장 세포 및 유전자 치료 소개

• 소개
• 세포치료
• 유전자 치료
• 세포 및 유전자 치료: 특징
• 인재 배치
• CAR-T의 제조 공정
• 세포 및 유전자 치료의 제조 공정
• 비용
• 상환
• 물류
• 합병과 인수
• 거래, 합의, 협업
• 규제 동향
• 파이프라인, 개발 개요
• 파이프라인, 개발 진척
• 질병 및 치료 영역별 파이프라인
• 제III상 개발
• 최종 사용자

제3장 종양학에서의 세포 및 유전자 치료 시장

• 개요
• 암 증식의 원인
  • 환경 요인, DNA, RNA
  • 세포암 유전자
  • 종양 억제 유전자
• 세계의 암 부담
• 시장 전망
• 주요 제품
• 연구개발 동향
  • 제III상 개발
• 세포 및 유전자 치료 시장 내역
• 지역 시장 요약
• 경쟁 요약

제4장 신경 관련 질환에의 세포 및 유전자 치료 시장

• 개요
• 시장 전망
• 주요 제품
• 연구개발 동향
  • 제III상 개발
• 세포 및 유전자 치료 시장 내역
• 지역 시장 요약
• 경쟁의 요약

제5장 근골격계 질환 및 장애에서의 세포 및 유전자 치료 시장

• 개요
• 시장 전망
• 주요 제품
• 연구개발 동향
  • 제III상 개발
• 세포 및 유전자 치료 시장 내역
• 지역 시장 요약
• 경쟁의 요약

제6장 심혈관 및 혈액 질환에서의 세포 및 유전자 치료 시장

• 개요
• 시장 전망
• 주요 제품
• 세포, 유전자, RNA 치료 시장 내역
• 심혈관 및 혈액 질환의 세포 및 유전자 치료 시장(적응증별)
• 지역 시장 요약
• 경쟁의 요약

제7장 피부과에서의 세포 및 유전자 치료 시장

• 개요
• 시장 전망
• 주요 제품
• 연구개발 동향
  • 제III상 개발
• 세포 및 유전자 치료 시장 내역
• 지역 시장 요약
• 경쟁의 요약

제8장 세포 및 유전자 치료 시장의 상황

• 개요
• 시장 전망
• 주요 제품
• 연구개발 동향
• 세포 및 유전자 치료 시장 내역
• 지역 시장 요약
• 경쟁의 요약

제9장 세포 및 유전자 치료 시장 리뷰

• 시장의 영향
• 세포 및 유전자 치료와 바이러스 벡터의 부족
• 세계 시장의 요약
• 세포 치료 시장과 유전자 치료 시장
• 지역 시장 개요
• 북미
• 유럽 및 EU
• 기타 국가
• 세포 및 유전자 치료 시장에서의 경쟁 랭킹

제10장 시장 진출기업

• 주요 영향력이 있는 기업
• AlloSource
• Alnylam Pharmaceuticals, Inc
• Amgen
• AnGes Inc
• Anterogen Co Ltd.
• Atara Biotherapeutics
• BioCardia
• Biogen, Inc.
• BioMarin Pharmaceuticals
• bluebird bio, Inc.
• BrainStorm Cell Therapeutics
• Bristol-Myers Squibb
• Candel Therapeutics
• Castle Creek Biosciences
• Celyad Oncology
• Cook Myosite, Inc
• Dendreon Pharmaceuticals
• Ferring Pharmaceuticals
• Gamida Cell Ltd.
• GenSight Biologics SA
• Gilead Sciences, Inc.
• Gradalis, Inc
• Helixmith
• Inovio Pharmaceuticals, Inc
• Medeor Therapeutics
• MEDIPOST Co, Ltd.
• MeiraGTx
• Mesoblast Ltd
• Northwest Biotherapeutics, Inc.
• Novartis AG
• NuVasive Biologics
• Orchard Therapeutics
• Organogenesis
• Orthofix
• Osiris Therapeutics, Inc.
• Pharmicell
• Pluristem Therapeutics, Inc.
• Sangamo Therapeutics
• Sanofi
• Sarepta Therapeutics
• Sotio as
• Spark Therapeutics
• uniQure NV
• Vericel Corporation

JHS

영문 목차

영문목차

The "Cell and Gene Therapy Market Dynamics by Disease Type: Development, Trends, and Forecasts, 4th Edition (2024-2030)" report by Kalorama Information explores the transformative potential of cell and gene therapies in modern medicine. These therapies offer groundbreaking treatments by addressing genetic causes of diseases and modulating the immune system. The report highlights the surge in new therapies and a promising pipeline, with significant clinical trial activity across various therapeutic areas, including oncology and cardiology.

This comprehensive report segments the market by therapeutic areas, providing detailed market estimates, forecasts, and insights into the competitive landscape. It covers global developments in cell, gene, and RNA therapy markets, focusing on key products, research trends, market breakdowns, regional revenues, and competitor analysis.

Key therapeutic areas covered include:

The report excludes RNA therapies for COVID-19 and mRNA vaccines for infectious diseases, focusing instead on broader gene therapy applications. It also omits cord blood products, considering their classification as transplants.

Methodologically, the report combines primary and secondary research, including interviews with industry participants and comprehensive literature reviews. It provides market highlights, forecasts, and competitive analyses, discussing market indicators, trends, and barriers. Given the nascent stage of gene therapies, forecasts are based on limited precedents, with market size estimates provided for 2024 and projections through 2030.

This report serves as a crucial resource for understanding the evolving landscape of cell and gene therapies, offering valuable insights for stakeholders in the healthcare and biotechnology sectors.

Table of Contents

Chapter 1: Executive Summary

• Overview
• Scope and Methodology
• Market Overview and Potential
  • Figure 1-1: Global Cell and Gene Therapy Market, by Product Segment, 2024-2030 ($ million) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
  • Table 1-1: Global Cell and Gene Therapy Market, by Product Segment, 2024-2030 ($ million) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
  • Figure 1-2: Global Share of Cell and Gene Therapy Market, by Product Segment, 2024 (%) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
  • Figure 1-3: Global Share of Cell and Gene Therapy Market, by Product Segment, 2029 (%) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]

Chapter 2: Introduction to Cell and Gene Therapy

• Introduction
  • Table 2-1: Total Numbers of Approved Cell, Gene, & RNA Therapies, by Type, 2022-2024, Global (count, %)
  • Figure 2-1: Share of Total Global Numbers of Approved Cell, Gene, & RNA Therapies, by Type, January 2025 (%)
• Cell Therapy
  • CAR T
  • Stem Cells
  • Adult Stem Cells
  • Human Embryonic Stem Cells
    • Table 2-2: Adult vs. Embryonic Stem Cells
• Gene Therapy
  • Table 2-3: Somatic vs. Germ Line Gene Therapy
  • Viral Vector System and New Developments
    • Table 2-4: Selected Examples of Viruses in Gene Therapy
    • Figure 2-2: Estimated Viral Vector Use in Commercialized Cell and Gene Therapies, by Type, 2022 (%)
  • Non-viral Systems for Transporting Genes
  • Gene Editing
• Cell and Gene Therapy: Characteristics
  • Table 2-5: Cell Therapy vs Gene Therapy
• Staffing
• Manufacturing Process for CAR-T
  • Leukapheresis
  • Activation
  • Transduction
  • Expansion
• Cell and Gene Therapy Manufacturing Processes
  • Table 2-6: Manufacturing Process Time for Select Autologous Cell and Gene Therapies [current and discontinued therapies]
  • Figure 2-3: Manufacturing Process Time for Select Autologous Cell and Gene Therapies [current and discontinued therapies]
• Cost
• Reimbursement
• Logistics
• Mergers and Acquisitions
  • Table 2-7: Selected Company Mergers and Acquisitions in the Cell and Gene Therapy Market
• Deals, Agreements, and Collaborations
• Regulatory Developments
  • Fast Track
  • Orphan Drug
  • Breakthrough Therapy
  • Accelerated Approval
  • Priority Review
    • Table 2-8: Regulatory Actions and Guidelines for Cell and Gene Therapy, by Select Country
  • Gene Therapy Approval Process
• Pipeline, Development Overview
• Pipeline, Development Progress
  • Table 2-9: Global Cell, Gene, & RNA Therapy Clinical Trial Growth (pre-clinical I through phase III), 2022-2024 (Count, %)
  • Figure 2-4: Global Cell, Gene, & RNA Therapy Development Progress (pre-clinical through phase III), as of Q4 2024
  • Table 2-10: Global Gene Therapy Pipeline, by Phase, 2022-2024 (count, %)
  • Figure 2-5: Global Gene Therapy Pipeline Shares by Phase, Q4 2024 (%)
• Pipeline by Condition and Therapeutic Area
  • Table 2-11: Global Cell, Gene, & RNA Therapy Pipeline, by Therapeutic Area, 2022-2024 (count, %) [Alimentary/Metabolic, Anticancer, Anti-infective, Blood and Clotting, Cardiovascular, Dermatological, Genitourinary (including sex hormones), Hormonal (excluding sex hormones), Immunological, Musculoskeletal, Neurological, Rare Diseases, Respiratory, Sensory, Miscellaneous, Other]
  • Figure 2-6: Global Gene Therapy Pipeline Shares, by Therapeutic Area, Q4 2024 (%) [Alimentary/Metabolic, Anticancer, Anti-infective, Blood and Clotting, Cardiovascular, Dermatological, Genitourinary (including sex hormones), Hormonal (excluding sex hormones), Immunological, Musculoskeletal, Neurological, Rare Diseases, Respiratory, Sensory, Miscellaneous, Other]
  • Table 2-12: Global Cell, Gene, & RNA Therapy Pipeline Excluding Pre-clinical, by Therapeutic Area, 2022-2024 (count, %) [Alimentary/Metabolic, Anticancer, Anti-infective, Blood and Clotting, Cardiovascular, Dermatological, Genitourinary (including sex hormones), Hormonal (excluding sex hormones), Immunological, Musculoskeletal, Neurological, Rare Diseases, Respiratory, Sensory, Miscellaneous, Other]
  • Table 2-13: Global Cell, Gene, & RNA Therapy Pipeline Excluding Pre-clinical, by Rare Disease, 2022-2024 (count, %) [Amyotrophic lateral sclerosis; Cancer, gastrointestinal, stomach; Cancer, leukemia, acute myelogenous; Cancer, leukemia, chronic lymphocytic; Cancer, liver; Cancer, lymphoma, B-cell; Cancer, lymphoma, B-cell, diffuse large; Cancer, lymphoma, non-Hodgkin's; Cancer, lymphoma, T-cell; Cancer, mesothelioma; Cancer, myeloma; Cancer, ovarian; Cancer, pancreatic; Cancer, renal; Cystic fibrosis; Dystrophy, Duchenne's muscular; Hemophilia A; Hemophilia B; Retinitis pigmentosa; Other]
  • Figure 2-7: Global Cell, Gene, & RNA Therapy Pipeline Excluding Pre-clinical, by Rare Disease, Share Q4 2024 (%) [Amyotrophic lateral sclerosis; Cancer, gastrointestinal, stomach; Cancer, leukemia, acute myelogenous; Cancer, leukemia, chronic lymphocytic; Cancer, liver; Cancer, lymphoma, B-cell; Cancer, lymphoma, B-cell, diffuse large; Cancer, lymphoma, non-Hodgkin's; Cancer, lymphoma, T-cell; Cancer, mesothelioma; Cancer, myeloma; Cancer, ovarian; Cancer, pancreatic; Cancer, renal; Cystic fibrosis; Dystrophy, Duchenne's muscular; Hemophilia A; Hemophilia B; Retinitis pigmentosa]
  • Table 2-14: Global Non-GM Cell Therapy Pipeline, by Therapeutic Area, 2022-2024 (count, %) [Alimentary/Metabolic, Anticancer, Anti-infective, Blood and Clotting, Cardiovascular, Dermatological, Genitourinary (including sex hormones), Hormonal (excluding sex hormones), Immunological, Musculoskeletal, Neurological, Rare Diseases, Respiratory, Sensory, NA/Unspecified]
  • Table 2-15: Global Non-GM Cell Therapy Pipeline, by Condition/Disease, 2022-2024 (count, %) [Alzheimer's disease; Arthritis, osteo; Cancer, brain; Cancer, breast; Cancer, leukemia, acute myelogenous; Cancer, liver; Cancer, lung, non-small cell; Cancer, melanoma; Cancer, ovarian; Cancer, solid, unspecified; Cancer, unspecified; COVID-19 complications; Diabetes, Type 1; Graft-versus-host disease; Heart failure; Hepatic dysfunction, unspecified; Infarction, myocardial; Ischemia, cerebral; Parkinson's disease; Respiratory distress syndrome, acute; Spinal cord injury]
  • Table 2-16: Global Non-GM Cell Therapy Pipeline, by Rare Disease Targeted, 2022-2024 (count, %) [Amyotrophic lateral sclerosis; Anal fistula; Cancer, gastrointestinal, stomach; Cancer, leukemia, acute myelogenous; Cancer, liver; Cancer, lymphoma, non-Hodgkin's; Cancer, myeloma; Cancer, ovarian; Cancer, pancreatic; Cancer, renal; Dystrophy, Duchenne's muscular; Epidermolysis bullosa; Fibrosis, pulmonary, idiopathic; Graft-versus-host disease; Huntington's disease; Myelodysplastic syndrome; Respiratory distress syndrome, acute; Retinitis pigmentosa; Spinal cord injury; Thalassemia]
  • Table 2-17: Global RNA Therapy Pipeline, by Therapeutic Area, 2022-2024 (count, %) [Alimentary/Metabolic, Anticancer, Anti-infective, Antiparasitic, Blood and Clotting, Cardiovascular, Dermatological, Genitourinary (including sex hormones), Hormonal (excluding sex hormones), Immunological, Musculoskeletal, Neurological, Rare Diseases, Respiratory, Sensory, Miscellaneous]
  • Table 2-18: Global RNA Therapy Pipeline, by Rare Disease Targeted, 2022-2024 (count, %) [Amyotrophic lateral sclerosis; Cancer, liver; Cancer, ovarian; Cancer, pancreatic; Cystic fibrosis; Dementia, frontotemporal; Dystrophy, Duchenne's muscular; Dystrophy, myotonic muscular; Fibrosis, pulmonary, idiopathic; Huntington's disease; Infection, malaria prophylaxis; Infection, rabies prophylaxis; Primary ciliary dyskinesia; Respiratory distress syndrome, acute]
• Phase III Development
  • Table 2-19: Phase III Development - Cell and Gene Therapies, Select Projects
• End Users
  • Hospitals
  • Research
  • Wound Care Centers
  • Cancer Centers

Chapter 3: Cell and Gene Therapy Markets in Oncology

• Overview
  • Biochemistry of Cancer Cells
• Causes of Cancer Growth
  • Environmental Factors, DNA, RNA
    • Table 3-1: Virus Association with Human Cancer
  • Cellular Oncogenes
  • Tumor Suppressor Genes
• Global Cancer Burden
  • Figure 3-1: Estimated Number of New Cancer Cases, Both Sexes, Age 0-85+, All Cancers, 2020 to 2040
  • Figure 3-2: Incidence of Cancer, by Type, 2020 [Bladder, Breast, Cervix Uteri, Colorectum, Liver, Lung, Oesophagus, Prostate, Stomach, Thyroid]
  • Figure 3-3: Worldwide Distribution of Cancer Incidence, by Type, 2020 [Breast, Cervix Uteri, Colorectum, Liver, Lung, Prostate, Stomach, Other Cancers]
• Market Outlook
  • Table 3-2: Cell, Gene, & RNA Therapy Markets in Oncology, 2024-2030 ($ million)
  • Figure 3-4: Cell, Gene, & RNA Therapy Markets in Oncology, 2024-2030 ($ million)
• Principal Products
  • Abecma
  • APCeden
  • Aucatzyl
  • Breyanzi
  • Carvykti
  • CreaVax-RCC
  • Delytact
  • Gendicine
  • Imlygic
  • Immuncell-LC
  • Kymriah
  • Provenge
  • Relma-cel
  • Rytelo
  • Tecartus
  • Tecelra
  • Yescarta
  • Zevor-cel
    • Table 3-3: Cell and Gene Therapy in Oncology
• Trends in Research and Development
  • Phase III Development
    • Table 3-4: Select Oncology Phase III Cell, Gene, & RNA Therapy Developments, through March 2025
• Market Breakdown of Cell and Gene Therapies
  • Table 3-5: Oncology Cell and Gene Therapy Markets, by Product Type, Estimated Sales 2024 and Projected 2030 Sales ($ million) [CAR-T, Cell Immunotherapy, Gene/Oligo/Conjugate Therapy, Other Cell]
  • Figure 3-5: Oncology Cell and Gene Therapy Market Distribution, by Product Type, 2024 (%) [CAR-T, Cell Immunotherapy, Gene Therapy]
  • Oncology Cell and Gene Therapy Market by Cancer Type
    • Table 3-6: Oncology Cell, Gene, & RNA Therapy Market, by Cancer Type, Estimated 2024 and Projected 2030 Sales ($ million) [Leukemia, Lymphoma, Melanoma, Multiple Myeloma, Prostate Cancer, Undefined Blood Cancer, Other Cancers]
    • Table 3-7: Oncology Cell, Gene, & RNA Therapy Market, by General Indication, 2024 (%) [Leukemia, Lymphoma, Melanoma, Multiple Myeloma, Prostate Cancer, Other Cancers]
    • Figure 3-6: Oncology Cell, Gene, & RNA Therapy Market, by General Indication, 2024 (%) [Leukemia, Lymphoma, Melanoma, Multiple Myeloma, Prostate Cancer, Other Cancers]
• Regional Market Summary
  • Table 3-8: Oncology Cell and Gene Therapy Market, by Country/Region, Estimated 2024 and Projected 2030 ($ million) [APAC, Europe, North America, ROW]
  • Figure 3-7: Oncology Cell and Gene Therapy Market, by Geographic Region, Estimated 2024 and Projected 2030 ($ million) [APAC, Europe, North America, ROW]
  • Figure 3-8: Oncology Cell and Gene Therapy Market Share, by Geographic Region, Estimated 2024 (%) [APAC, Europe, North America, ROW]
• Competitor Summary
  • Table 3-9: Oncology Cell, Gene, & RNA Therapy Competitor Sales and Market Share, Reported and Estimated 2024 ($ million, %) [BMS, Dendreon, Gilead/Kite, Janssen, Novartis, Others]
  • Figure 3-9: Oncology Cell, Gene, & RNA Therapy Competitor Sales, Estimated 2024 ($ million) [BMS, Dendreon, Gilead/Kite, Janssen, Novartis, Others]
  • Figure 3-10: Oncology Cell, Gene, & RNA Therapy Competitor Market Share, Estimated 2024 (%) [BMS, Dendreon, Gilead/Kite, Janssen, Novartis, Others]

Chapter 4: Cell and Gene Therapy Markets in Neurological-Related Disorders

• Overview
• Market Outlook
  • Table 4-1: Cell, Gene, and RNA Therapies in Neurological-Related Conditions, 2024-2030 ($ million)
  • Figure 4-1: Cell, Gene, and RNA Therapies in Neurological-Related Conditions, 2024-2030 ($ million)
• Principal Products
  • Amvuttra
  • Libmeldy/ Lenmeldy
  • NeuroNata-R
  • Onpattro
  • SKYSONA
  • Spinraza
  • Stemirac
  • Upstaza
  • Wainua
  • Zolgensma
    • Table 4-2: Cell, Gene, and RNA Therapy in Neurological Diseases and Disorders
• Trends in Research and Development
  • Phase III Development
    • Table 4-3: Select Neurological Phase III Cell and Gene Therapy Developments, through January 2025
• Market Breakdown of Cell and Gene Therapies
  • Table 4-4: Neurological Conditions Cell and Gene Therapy Markets, by Product Type, Estimated 2024 and Projected 2030 Sales ($ million) [Cell Therapy, Gene Therapy, RNA/Antisense Therapy]
  • Figure 4-2: Neurological Conditions Cell, Gene, & RNA Therapy Market Distribution, by Product Type, 2024 (%) [Cell Therapy, Gene Therapy, RNA/Antisense Therapy]
• Regional Market Summary
  • Table 4-5: Neurological Conditions Cell and Gene Therapy Market, by Country/Region, Estimated 2024 and Projected 2030 ($ million) [APAC, Europe, North America, ROW]
  • Figure 4-3: Neurological Conditions Cell, Gene, & RNA Therapy Market Summary, by Geographic Region, Estimated 2024 and Projected 2030 ($ million) [APAC, Europe, North America, ROW]
• Competitor Summary
  • Table 4-6: Neurological Conditions Cell and Gene Therapy Competitor Sales and Market Share, Reported and Estimated 2024 ($ million, %) [Alnylam Pharmaceuticals, Biogen, Novartis, Others]
  • Figure 4-4: Neurological Conditions Cell, Gene, & RNA Therapy Market Shares, by Company, Estimated 2024 ($ million) [Alnylam Pharmaceuticals, Biogen, Novartis, Others]

Chapter 5: Cell and Gene Therapy Markets in Musculoskeletal Conditions and Disorders

• Overview
• Market Outlook
  • Table 5-1: Cell, Gene, & RNA Therapy Markets in Musculoskeletal Conditions and Disorders, 2024-2030 ($ million)
  • Figure 5-1: Cell, Gene, & RNA Therapy Markets in Musculoskeletal Conditions and Disorders, 2024-2030 ($ million)
• Principal Products
  • AlloStem
  • Amondys
  • BIO4
  • Carticel
  • Cartiform
  • CartiLife
  • Cartistem
  • Chondron
  • Elevidys
  • Exondys
  • JACC
  • MACI
  • Ortho-ACI and Ortho-ATI
  • Ossron
  • Osteocel and Osteoplus
  • Spherox
  • Trinity Elite and Trinity Evolution
  • Vyondys
    • Table 5-2: Cell and Gene Therapies in Musculoskeletal Diseases and Disorders
• Trends in Research and Development
  • Phase III Development
    • Table 5-3: Select Musculoskeletal Phase III Cell and Gene Therapy Developments, through January 2025
• Market Breakdown of Cell and Gene Therapies
  • Table 5-4: Musculoskeletal Cell, Gene, & RNA Therapy Markets, by Product Type, Estimated 2024 and Projected 2030 Sales ($ million)
  • Musculoskeletal Cell and Gene Therapy Market by Indication
    • Table 5-5: Musculoskeletal Cell, Gene, & RNA Therapy Market, by General Indication, Estimated 2024 and Projected 2030 Sales ($ million) [Bone Defect/Damage Repair, Cartilage Defect/Damage Repair, DMD, Others (Tendon Damage, Osteoarthritis)]
    • Figure 5-2: Musculoskeletal Cell, Gene, & RNA Therapy Market, by General Indication, Estimated 2024 (%) [Bone Defect/Damage Repair, Cartilage Defect/Damage Repair, DMD, Others (Tendon Damage, Osteoarthritis)]
• Regional Market Summary
  • Figure 5-3: Musculoskeletal Cell, Gene, & RNA Therapy Market, by Country/Region, Estimated 2024 (%) [APAC, Europe, United States, ROW]
  • Table 5-6: Musculoskeletal Cell, Gene, & RNA Therapy Market, by Country/Region, 2024 and Projected 2030 Sales ($ million) [APAC, Europe, United States, ROW]
  • Figure 5-4: Musculoskeletal Cell and Gene Therapy Market Summary, by Geographic Region, Estimated 2024 and Projected 2030 Sales ($ million) [APAC, Europe, United States, ROW]
• Competitor Summary
  • Table 5-7: Musculoskeletal Cell, Gene, & RNA Therapy Competitor Market Share, Reported and Estimated 2024 ($ million) [Sarepta, Vericel, Other Companies]
  • Figure 5-5: Musculoskeletal Cell, Gene, & RNA Therapy Market Shares, by Company, Estimated 2024 (%) [Sarepta, Vericel, Other Companies]

Chapter 6: Cell and Gene Therapy Markets in Cardiovascular and Blood Disorders

• Overview
  • Cardiovascular Disease
  • Selected Blood Disorders
• Market Outlook
  • Table 6-1: Cell, Gene, and RNA Therapy Markets in Cardiovascular and Blood Disorders, 2024-2030 ($ million)
  • Figure 6-1: Cell, Gene, and RNA Therapy Markets in Cardiovascular and Blood Disorders, 2024-2030 ($ million)
• Principal Products
  • Collategene
  • Hearticellgram
  • HeartSheet
  • Leqvio
  • Neovasculgen
  • Stempeucel
  • Zynteglo
    • Table 6-2: Selected Cell and Gene Therapy in Cardiovascular and Blood Disorders
  • Phase III Development
    • Table 6-3: Select Cardiovascular and Blood Disorder in Phase III Cell and Gene Therapy Developments, through January 2025
• Market Breakdown of Cell, Gene, and RNA Therapies
  • Table 6-4: Cardiovascular and Blood Disorders Cell, Gene, & RNA Therapy Markets, by Product Type, Estimated 2024 and Projected 2030 Sales ($ million) [Cell-based Gene Therapy, Non-GM Cell, RNA, Other Gene Therapies]
  • Figure 6-2: Cardiovascular and Blood Disorders Cell and Gene Therapy Market Distribution, by Product Type, 2024 (%) [Cell-based Gene Therapy, Non-GM Cell, RNA, Other Gene Therapies]
• Cardiovascular and Blood Disorders Cell and Gene Therapy Market by Indication
  • Table 6-5: Cardiovascular and Blood Disorders Cell and Gene Therapy Market, by General Indication, Estimated 2024 and Projected 2030 Sales ($ million) [Blood, Cardiac, Hypercholesterolemia, Vascular]
• Regional Market Summary
  • Table 6-6: Cardiovascular and Blood Disorders Cell and Gene Therapy Market, by Country/Region, Estimated 2024 and Projected 2030 ($ million) [APAC, Europe, North America, ROW]
  • Figure 6-3: Cardiovascular and Blood Disorders Cell and Gene Therapy Market Summary, by Geographic Region, Estimated 2024 and Projected 2030 Sales ($ million) [APAC, Europe, North America, ROW]
  • Figure 6-4: Cardiovascular and Blood Disorders Cell and Gene Therapy Market Share, by Geographic Region, Estimated 2024 (%) [APAC, Europe, North America, ROW]
• Competitor Summary

Chapter 7: Cell and Gene Therapy Markets in Dermatology

• Overview
  • Table 7-1: Wound Prevalence, by Type [Skin Ulcers: Pressure Injuries, Venous Statis Ulcers, Diabetic Ulcers and Burns: Outpatient Burns, Hospitalized Burns, and Medically Treated Burns]
• Market Outlook
  • Table 7-2: Cell and Gene Therapy Markets in Dermatology, 2024-2030 ($ million)
  • Figure 7-1: Cell and Gene Therapy Markets in Dermatology, 2024-2030 ($ million)
• Principal Products
  • Adipocel
  • Apligraf
  • CureSkin
  • Dermagraft
  • Epicel
  • Grafix
  • Holoderm
  • Kaloderm
  • KeraHeal/KeraHeal-Allo
  • LaViv
  • Orcel
  • Quencell
  • RECELL
  • Rosmir
  • Stempeutics/Cutisera
  • StrataGraft
  • Stravix
  • TransCyte
  • Vyjuvek
    • Table 7-3: Cell and Gene Therapy in Dermatological Diseases and Disorders
• Trends in Research and Development
  • Phase III Development
    • Table 7-4: Select Dermatology Phase III Cell and Gene Therapy Developments, through January 2025
• Market Breakdown of Cell and Gene Therapies
  • Table 7-5: Dermatology Cell and Gene Therapy Markets, by Product Type, Estimated 2024 and Projected 2030 Sales ($ million) [Stem Cells, Skin Cells, Gene/Gene-Modified Cell Therapy]
  • Figure 7-2: Dermatology Cell and Gene Therapy Market Distribution, by Product Type, 2024 (%) [Stem Cells, Skin Cells, Gene/Gene-Modified Cell Therapy]
  • Dermatology Cell and Gene Therapy Market by Indication
• Regional Market Summary
  • Table 7-6: Dermatology Cell and Gene Therapy Market, by Country/Region, Estimated 2024 & Projected 2030 Sales ($ million) [APAC, Europe, North America, ROW]
  • Figure 7-3: Dermatology Cell and Gene Therapy Market Summary, by Geographic Region, Estimated 2024 and Projected 2030 ($ million) [APAC, Europe, North America, ROW]
  • Figure 7-4: Dermatology Cell and Gene Therapy Market Share, by Geographic Region, 2024 (%) [APAC, Europe, North America, ROW]
• Competitor Summary
  • Table 7-7: Dermatology Cell and Gene Therapy Competitor Sales and Market Share, Reported and Estimated 2024 ($ million) [Krystal Biotech, Organogenesis, Smith & Nephew (Osiris), Vericel, Other]
  • Figure 7-5: Dermatology Cell and Gene Therapy Market Share, by Company, Estimated 2024 (%) [Krystal Biotech, Organogenesis, Smith & Nephew (Osiris), Vericel, Other]

Chapter 8: Cell and Gene Therapy Markets in Other Conditions

• Overview
• Market Outlook
  • Figure 8-1: Cell and Gene Therapy Markets in Other Conditions, 2024-2030 ($ million)
  • Table 8-1: Cell and Gene Therapy Markets in Other Conditions, 2024-2030 ($ million)
• Principal Products
  • Alofisel
  • Cupistem
  • Givlaari
  • Glybera
  • Holoclar
  • Luxturna
  • Oxlumo
  • Rethymic
  • Ryoncil/ Prochymal/ Temcell
  • Tryngolza
    • Table 8-2: Cell and Gene Therapy in Other Diseases and Disorders
• Trends in Research and Development
• Market Breakdown of Cell and Gene Therapies
  • Table 8-3: Other Conditions Cell and Gene Therapy Markets, by Product Type, Estimated 2024 and Projected 2030 Sales ($ million) [Cell-based Gene Therapy; RNA, Antisense Etc.; Stem Cell & Other Cell Therapy; Other Gene Therapy]
  • Figure 8-2: Other Conditions Cell and Gene Therapy Market Distribution, by Product Type, 2024 (%) [Cell-based Gene Therapy; RNA, Antisense Etc.; Stem Cell & Other Cell Therapy; Other Gene Therapy]
• Regional Market Summary
  • Table 8-4: Other Conditions Cell and Gene Therapy Market, by Country/Region, Estimated 2024 and Projected 2030 ($ million) [Europe, North America, ROW]
  • Figure 8-3: Other Conditions Cell and Gene Therapy Market Summary, by Geographic Region, Estimated 2024 and Projected 2030 ($ million) [Europe, North America, ROW]
  • Figure 8-4: Other Conditions Cell and Gene Therapy Market Share, by Geographic Region, Estimated 2024 (%) [Europe, North America, ROW]
• Competitor Summary

Chapter 9: Cell and Gene Therapy Market Review

• Market Influences
  • Global Demographics
    • Table 9-1: Global Population, 1980-2050 (population in millions)
  • Aging Population
    • Figure 9-1: Global Population Trends, Total Population vs. Age 65+ Population, 2000-2050
  • Cost Containment
    • Table 9-2: Cost Comparisons for Selected Commercialized Cell and Gene Therapies
• Cell and Gene Therapy and Viral Vector Shortages
• Global Market Summary
  • Table 9-3: Cell, Gene, and RNA Therapy Market Summary, by Disease Segment, 2024-2030 ($ million) [Cardio/non-oncology blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
  • Figure 9-2a: Cell, Gene, and RNA Therapy Market Summary, by Disease Segment, 2024-2030 ($ million) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
  • Figure 9-2b: Cell, Gene, and RNA Therapy Market Summary, by Disease Segment, 2024-2030 ($ million) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
  • Figure 9-3: Cell and Gene Therapy Market, Distribution of Sales by Disease Segment, 2024 [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
• Cell vs. Gene Therapy Markets
  • Table 9-4: Cell, Gene, & RNA Therapy Market Summary, by Method, 2024-2030 ($ million)
  • Figure 9-4: Cell, Gene, & RNA Therapy Market, Distribution of Sales, by Method, 2024 (%)
  • Figure 9-5: Cell, Gene, & RNA Therapy Market, Distribution of Sales, by Method, 2029 (%)
• Regional Market Overview
  • Table 9-5: Cell, Gene, & RNA Therapy Market Summary by Geographical Region, 2024-2030 ($ million) [Europe, North America, ROW]
• North America
  • Table 9-6: Cell, Gene, & RNA Therapy Market Summary for United States, by Product Segment, 2024-2030 ($ million) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
  • Table 9-7: Cell, Gene, & RNA Therapy Market Summary for United States, by Product Segment, 2024-2030 ($ million) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
  • Figure 9-6: U.S. Cell and Gene Therapy Market, Distribution by Product Segment, 2024 (%) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
  • Table 9-8: Major Cell and Gene Therapy Product Approvals, FDA
• Europe/European Union
  • Table 9-9: Cell, Gene, & RNA Therapy Market Summary for Europe/European Union, by Disease Area, 2024-2030 ($ million) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
  • Figure 9-7: Cell, Gene, & RNA Therapy Market Summary for Europe/European Union, by Disease Area, 2024-2030 ($ million) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
  • Figure 9-8: Europe Cell and Gene Therapy Market, Distribution by Product Segment, 2024 (%) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
  • Table 9-10: Major Cell and Gene Therapy Approvals by EMA
• Other Countries
  • Table 9-11: Cell, Gene, & RNA Therapy Market Summary for Other Countries, by Disease Segment, 2024-2030 ($ million) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
  • Figure 9-9: Cell, Gene, & RNA Therapy Market Summary for Other Countries, by Disease Segment, 2024-2030 ($ million) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
  • Figure 9-10: ROW Cell, Gene, & RNA Therapy Market, Distribution by Disease Segment, 2024 (%) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
  • Table 9-12: Select Major Cell and Gene Therapy Approvals by Various Regulatory Authorities
• Competitor Ranking in Cell and Gene Therapy Markets
  • Table 9-13: Estimated Cell and Gene Therapy Sales by Leading Competitors, 2024 Sales ($ million) [Alnylam, BMS, Biogen, Janssen, Kite/Gilead, Novartis, Sarepta, Other]
  • Figure 9-11: Estimated Cell and Gene Therapy Sales by Leading Competitors, 2024 Sales ($ million) [Alnylam, BMS, Biogen, Janssen, Kite/Gilead, Novartis, Sarepta, Other]
  • Figure 9-12: Cell and Gene Therapy Market Share Estimates by Leading Competitors, 2024 (%) [Alnylam, BMS, Biogen, Janssen, Kite/Gilead, Novartis, Sarepta, Other]

Chapter 10: Market Participants

• Leading Influencers
• AlloSource
  • Table 10-1: AlloSource Corporate Summary
  • Company Summary
  • Products
• Alnylam Pharmaceuticals, Inc.
  • Table 10-2: Alnylam Pharmaceuticals Corporate Summary
  • Company Summary
  • Products
• Amgen
  • Table 10-3: Amgen Corporate Summary
  • Company Summary
  • Products
• AnGes Inc.
  • Table 10-4: AnGes Corporate Summary
  • Company Summary
  • Products
• Anterogen Co Ltd.
  • Table 10-5: Anterogen Corporate Summary
  • Company Summary
  • Products
• Atara Biotherapeutics
  • Table 10-6: Atara Biotherapeutics Corporate Summary
  • Company Summary
  • Products
• BioCardia
  • Table 10-7: BioCardia Summary
  • Company Summary
  • Products
  • Projects in the pipeline using the CardiAMP system include:
  • Projects in the pipeline using the CardiALLO system include:
• Biogen, Inc.
  • Table 10-8: Biogen Corporate Summary
  • Company Summary
  • Products
• BioMarin Pharmaceuticals
  • Table 10-9: BioMarin Pharmaceuticals Corporate Summary
  • Company Summary
  • Products
• bluebird bio, Inc.
  • Table 10-10: bluebird bio Corporate Summary
  • Company Summary
  • Products
• BrainStorm Cell Therapeutics
  • Table 10-11: BrainStorm Cell Therapeutics Corporate Summary
  • Company Summary
  • Products
• Bristol-Myers Squibb
  • Table 10-12: Bristol-Myers Squibb Corporate Summary
  • Company Summary
  • Products
• Candel Therapeutics
  • Table 10-13: Candel Therapeutics Corporate Summary
  • Company Summary
  • Products
  • In the pipeline, the company offers:
• Castle Creek Biosciences
  • Table 10-14: Castle Creek Corporate Summary
  • Company Summary
  • Products
• Celyad Oncology
  • Table 10-15: Celyad Oncology Corporate Summary
  • Company Summary
  • Products
• Cook Myosite, Inc
  • Table 10-16: Cook Myosite Corporate Summary
  • Company Summary
  • Products
• Dendreon Pharmaceuticals (Sanpower)
  • Table 10-17: Dendreon Corporate Summary
  • Company Summary
  • Products
• Ferring Pharmaceuticals
  • Table 10-18: FerGene Corporate Summary
  • Company Summary
  • Products
• Gamida Cell Ltd.
  • Table 10-19: Gamida Cell Corporate Summary
  • Company Summary
  • Products
• GenSight Biologics S.A.
  • Table 10-20: GenSight Biologics Corporate Summary
  • Company Summary
  • Products
• Gilead Sciences, Inc.
  • Table 10-21: Gilead Sciences Corporate Summary
  • Company Summary
  • Products
• Other selected indications in the pipeline include:
• Gradalis, Inc
  • Table 10-22: Gradalis Corporate Summary
  • Company Summary
  • Products
• Helixmith
  • Table 10-23: Helixmith Corporate Summary
  • Company Summary
  • Products
• Inovio Pharmaceuticals, Inc.
  • Table 10-24: Inovio Pharmaceuticals Corporate Summary
  • Company Summary
  • Products in the Pipeline
• Medeor Therapeutics
  • Table 10-25: Medeor Therapeutics Corporate Summary
  • Company Summary
  • Products
• MEDIPOST Co, Ltd.
  • Table 10-26: MEDIPOST Corporate Summary
  • Company Summary
  • Products
• MeiraGTx
  • Table 10-27: MeiraGTx Corporate Summary
  • Company Summary
  • Products
• Mesoblast Ltd.
  • Table 10-28: Mesoblast Corporate Summary
  • Company Summary
  • Products
• Northwest Biotherapeutics, Inc.
  • Table 10-29: Northwest Biotherapeutics Corporate Summary
  • Company Summary
  • Products
• Novartis AG
  • Table 10-30: Novartis Corporate Summary
  • Company Summary
  • Products
  • Other Current Projects
• NuVasive Biologics
  • Table 10-31: NuVasive Biologics Corporate Summary
  • Company Summary
  • Products
• Orchard Therapeutics
  • Table 10-32: Orchard Therapeutics Corporate Summary
  • Company Summary
  • Products
• Organogenesis
  • Table 10-33: Organogenesis Corporate Summary
  • Company Summary
  • Products
• Orthofix
  • Table 10-34: Orthofix Corporate Summary
  • Company Summary
  • Products
• Osiris Therapeutics, Inc. (Smith & Nephew)
  • Table 10-35: Osiris Corporate Summary
  • Company Summary
  • Products
• Pharmicell
  • Table 10-36: Pharmicell Corporate Summary
  • Company Summary
  • Products
• Pluristem Therapeutics, Inc.
  • Table 10-37: Pluristem Therapeutics Corporate Summary
  • Company Summary
  • Products
• Sangamo Therapeutics
  • Table 10-38: Sangamo Therapeutics Corporate Summary
  • Company Summary
  • Products
• Sanofi
  • Table 10-39: Sanofi Corporate Summary
  • Company Summary
• Sarepta Therapeutics
  • Table 10-40: Sarepta Corporate Summary
  • Company Summary
  • Products
• Sotio a.s.
  • Table 10-41: Sotio Corporate Summary
  • Company Summary
  • Products
• Spark Therapeutics
  • Table 10-42: Spark Therapeutics Corporate Summary
  • Company Summary
  • Products
  • Pipeline Projects
• uniQure N.V.
  • Table 10-43: uniQure Corporate Summary
  • Company Summary
  • Products
• Vericel Corporation
  • Table 10-44: Vericel Corporate Summary
  • Company Summary
  • Products

관련자료